Condition: Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma · Sponsor: City of Hope Medical Center
This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving leflunomide with pomalidomide and dexamethasone may work better in treating multiple myeloma compared to pomalidomide and dexamethasone alone.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Medical Center | Duarte, California, United States | Recruiting |
| City of Hope at Seacliff | Huntington Beach, California, United States | Recruiting |
| City of Hope at Antelope Valley | Lancaster, California, United States | Recruiting |
| City of Hope at Long Beach Elm | Long Beach, California, United States | Recruiting |
| City of Hope at Newport Beach Fashion Island | Newport Beach, California, United States | Recruiting |
| City of Hope at South Pasadena | South Pasadena, California, United States | Recruiting |
| City of Hope at South Bay | Torrance, California, United States | Recruiting |
| City of Hope at Upland | Upland, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04508790